Lon: trx

This website uses cookies so that we can provide you with the best user experience possible.

Tissue Regenix Group plc is a medical device company in regenerative medicine. The principal activity of the Company is the exploitation of platform technologies in the field of bone graft substitutes and soft tissue. It is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. The Company's patented decellularization technology dCELL removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Its proprietary BioRinse technology platform is primarily utilized to provide sterile tissue prepared in a manner to minimize the negative effects of processing. GBM-V produces tissue preparations for ophthalmology, primarily cornea, using conventional, classical methods.

Lon: trx

We could not find any results for: Make sure your spelling is correct or try broadening your search. It looks like you aren't logged in. Click the button below to log in and view your recent history. Already a member? Sign in. More Brokers. It looks like you are not logged in. Click the button below to log in and keep track of your recent history. Clear Search. Trending Now.

The overall consensus recommendation for Tissue Regenix is Buy, lon: trx. The Tissue Regenix PE ratio based on its reported earnings over the past 12 months is Tomorrow will be telling ifvwe close over

.

GBX Key events shows relevant news articles on days with large price movements. TBCG 0. Georgia Capital PLC. CGEO 0. Indivior PLC. INDV 0. The Motley Fool. Yahoo Finance. Super Micro Computer Inc.

Lon: trx

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United States and internationally. View our latest analysis for Tissue Regenix Group. Consensus from 2 of the British Biotechs analysts is that Tissue Regenix Group is on the verge of breakeven. Therefore, the company is expected to breakeven roughly 2 years from now. In order to meet this breakeven date, we calculated the rate at which the company must grow year-on-year. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Gerçeğin peşinde son

Total Revenue. This website uses cookies. Read Full Thread Reply. So in general terms, the higher the PE, the more expensive the stock is. Quick Ratio. Read Full Thread. Free Cashflow ps. About Market data Factfile News archive Visit company website. Create a customised news feed, and subscribe to our regional newsletters. Broken up out of a channel on volume, target London Stock Exchange. What brokers say Tissue Regenix: Broker initiates coverage with 1. Already a member?

But that doesn't change the fact that the returns over the last half decade have been stomach churning. While the recent increase might be a green shoot, we're certainly hesitant to rejoice.

It looks like you aren't logged in. Similar to TRX. It looks like you are not logged in. Dividend Yield f. Asset Turnover. Recs Turnover. Register or. Strictly Necessary and Functional. PE Ratio Range. The principal activity of the Company is the exploitation of platform technologies in the field of bone graft substitutes and soft tissue. Tissue Regenix dispatches allograft EU orders after Irish facility green light Tissue Regenix's new hub creates 'significant opportunity' - broker Tissue Regenix Group says "disciplined approach" paying off at half-year stage. Companies News. The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. EPS Growth. Advertise Here.